丹麦2型糖尿病合并心血管疾病患者中衰弱程度与SGLT2抑制剂及GLP-1受体激动剂起始治疗的关系:一项横断面全国性研究
BACKGROUND: Whether frailty influences the initiation of two cardioprotective diabetes drug therapies (ie, SGLT2 inhibitors and GLP-1 receptor agonists) in people with type 2 diabetes and cardiovascular disease is unknown.…
要点
- 衰弱患者起始SGLT2抑制剂或GLP-1受体激动剂的概率显著低于非衰弱者。
- 该关联在调整年龄、性别、社会经济状况、多重用药和共病后仍持续存在。
核心结论
- 在丹麦2型糖尿病合并心血管疾病患者中,衰弱与SGLT2抑制剂或GLP-1受体激动剂起始治疗概率显著降低相关。
研究设计与样本
- 排除年龄小于40岁、终末期肾病、有SGLT2抑制剂或GLP-1受体激动剂禁忌症或既往使用过任一药物者。
- 采用医院衰弱风险评分将患者分为非衰弱、中度衰弱和重度衰弱,使用Cox比例风险模型分析衰弱与起始治疗的关系。
主要发现
- 调整年龄、性别、社会经济状况、入组年份、2型糖尿病病程、心血管疾病病程、多重用药和共病后,关联持续存在。
关键数值与推荐
- 衰弱程度采用医院衰弱风险评分分类为非衰弱、中度衰弱和重度衰弱。
临床怎么用
- 在2型糖尿病合并心血管疾病的衰弱患者中,应关注SGLT2抑制剂和GLP-1受体激动剂起始治疗不足的问题。
- 建议制定明确且更新的指南,指导衰弱合并2型糖尿病和心血管疾病患者使用SGLT2抑制剂和GLP-1受体激动剂。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Whether frailty influences the initiation of two cardioprotective diabetes drug therapies (ie, SGLT2 inhibitors and GLP-1 receptor agonists) in people with type 2 diabetes and cardiovascular disease is unknown. We aimed to assess rates of initiation of SGLT2 inhibitors and GLP-1 receptor agonists according to frailty in people with type 2 diabetes and cardiovascular disease. METHODS: For this cross-sectional, nationwide study, all people with type 2 diabetes and cardiovascular disease in Denmark between Jan 1, 2015, and Dec 31, 2021, from six Danish health-data registers were identified. People younger than 40 years, with end-stage renal disease, with registered contraindications to SGLT2 inhibitors or GLP-1 receptor agonists, or with previous use of either drug therapy were excluded. The Hospital Frailty Risk Score was used to categorise people as either non-frail, moderately frail, or severely frail. Cox proportional hazards models were used to analyse the association between frailty and initiation of an SGLT2 inhibitor or a GLP-1 receptor agonist. FINDINGS: Of 119 390 people with type 2 diabetes and cardiovascular disease, 103 790 were included. Median follow-up time was 4·5 years (IQR 2·7-6·1) and median age across the three frailty groups was 71 years (64-79). 65 959 (63·6%) of 103 790 people were male and 37 831 (36·5%) were female. At index date, 66 910 (64·5%) people were non-frail, 29 250 (28·2%) were moderately frail, and 7630 (7·4%) were severely frail. Frailty was associated with a significantly lower probability of initiating therapy with an SGLT2 inhibitor or a GLP-1 receptor agonist than in people who were non-frail (moderately frail hazard ratio 0·91, 95% CI 0·88-0·94, p<0·0001; severely frail 0·75, 0·70-0·80, p<0·0001). This association persisted after adjustment for age, sex, socioeconomic status, year of inclusion, duration of type 2 diabetes, duration of cardiovascular disease, polypharmacy, and comorbidity. INTERPRETATION: In people with type 2 diabetes and cardiovascular disease in Denmark, frailty was associated with a significantly lower probability of SGLT2-inhibitor or GLP-1 receptor-agonist initiation, despite their benefits. Formulating clear and updated guidelines on the use of SGLT2 inhibitors and GLP-1 receptor agonists in people who are frail with type 2 diabetes and cardiovascular disease should be a priority. FUNDING: Department of Cardiology, Herlev and Gentofte University Hospital. TRANSLATION: For the Danish translation of the abstract see Supplementary Materials section.
引用
- Malik ME, Butt JH, Strange JE, et al. Initiation of SGLT2 inhibitors and GLP-1 receptor agonists according to level of frailty in people with type 2 diabetes and cardiovascular disease in Denmark: a cross-sectional, nationwide study. Lancet Healthy Longev. 2023. PMID: 37734395. doi:10.1016/S2666-7568(23)00164-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。